Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $250,639.00 in Stock

Key Points

• COO Julie Rubinstein sold 19,060 shares on April 13 at an average price of $13.15 for $250,639, reducing her direct holdings to 421,174 shares (a 4.33% decrease); the transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
• The April 13 sale is part of a sustained insider selling program that included multiple transactions in March and April, notably a 141,583‑share sale on March 11 worth about $1.88 million, signaling substantial insider liquidation over the period.
• For context, ADPT traded around $14.13 midday with a market cap of about $2.18 billion, recent quarterly results beat revenue estimates, and analysts show a consensus rating of "Moderate Buy" with a consensus target of $18.25 (several firms have raised targets to $21).

Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) COO Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock in a transaction that occurred on Monday, April 13th. The stock was sold at an average price of $13.15, for a total value of $250,639.00. Following the completion of the transaction, the chief operating officer directly owned 421,174 shares in the company, valued at approximately $5,538,438.10. This represents a 4.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

• On Friday, April 10th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $12.77, for a total value of $243,396.20.
• On Tuesday, April 7th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.56, for a total value of $258,453.60.
• On Wednesday, April 8th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.83, for a total value of $458,855.03.
• On Wednesday, April 1st, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.45, for a total value of $275,417.00.
• On Monday, March 23rd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.83, for a total value of $263,599.80.
• On Friday, March 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.37, for a total value of $254,832.20.
• On Wednesday, March 18th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.18, for a total value of $251,210.80.
• On Monday, March 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.41, for a total value of $255,594.60.
• On Wednesday, March 11th, Julie Rubinstein sold 141,583 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.29, for a total value of $1,881,638.07.
• On Friday, March 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $12.96, for a total value of $247,017.60.

Adaptive Biotechnologies Price Performance

Shares of Adaptive Biotechnologies stock traded up $1.34 during midday trading on Monday, reaching $14.13. The company had a trading volume of 3,126,145 shares, compared to its average volume of 1,989,528. The stock has a fifty day moving average price of $14.87 and a 200 day moving average price of $15.99. The firm has a market cap of $2.18 billion, a PE ratio of -35.32 and a beta of 2.29. Adaptive Biotechnologies Corporation has a fifty-two week low of $6.77 and a fifty-two week high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.10. The business had revenue of $71.68 million during the quarter, compared to the consensus estimate of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm's revenue for the quarter was up 51.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.23) earnings per share. As a group, sell-side analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Guggenheim lifted their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a "buy" rating in a report on Monday, January 26th. TD Cowen reiterated a "buy" rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Wall Street Zen downgraded Adaptive Biotechnologies from a "buy" rating to a "hold" rating in a report on Saturday, March 7th. JPMorgan Chase & Co. lifted their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an "overweight" rating in a report on Friday, February 6th. Finally, Piper Sandler set a $21.00 target price on Adaptive Biotechnologies in a report on Friday, February 6th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Adaptive Biotechnologies has an average rating of "Moderate Buy" and a consensus price target of $18.25.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several hedge funds and other institutional investors have recently modified their holdings of ADPT. Westfield Capital Management Co. LP bought a new stake in shares of Adaptive Biotechnologies during the fourth quarter valued at approximately $65,942,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Adaptive Biotechnologies by 303.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company's stock valued at $71,252,000 after acquiring an additional 3,299,635 shares in the last quarter. Ameriprise Financial Inc. increased its holdings in shares of Adaptive Biotechnologies by 84.3% during the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company's stock valued at $89,337,000 after acquiring an additional 2,731,648 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Adaptive Biotechnologies by 248.8% during the fourth quarter. Invesco Ltd. now owns 3,107,653 shares of the company's stock valued at $50,468,000 after acquiring an additional 2,216,595 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its holdings in shares of Adaptive Biotechnologies by 544.0% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company's stock valued at $36,523,000 after acquiring an additional 2,062,282 shares in the last quarter. Institutional investors own 99.17% of the company's stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.